natgillin/translations-raw huggingface dataset:
is an unsubstituted or substituted hydroxyl group; is a hydrogen atom or an unsubstituted or substituted C1-8 alkyl group; and is a hydrogen atom, an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-5 cycloalkyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted C1-8 alkoxycarbonyl group, an unsubstituted or substituted hydroxyl group, or a cyano group. 
R' je nesupstituirana ili supstituirana hidroksilna skupina, R? je vodikov atom ili nesupstituirana ili supstituirana skupina C,.g alkil i R> je vodikov atom, nesupstituirana ili supstituirana skupina C,.g alkil, nesupstituirana ili supstituirana skupina C2g alkenil, nesupstituirana ili supstituirana skupina Cxg alkinil, nesupstituirana ili supstituirana skupina Cas cikloalkil, nesupstituirana ili supstituirana skupina Co aril, nesupstituirana ili supstituirana heterociklička skupina, nesupstituirana ili supstituirana skupina C,g acil, nesupstituirana ili supstituirana skupina (1-imino)C;g alkil, nesupstituirana ili supstituirana skupina Cia alkoksikarbonil, nesupstituirana ili supstituirana hidroksilna skupina, ili cijano skupina;
Alternatively, permanent-magnetic material may be applied to the surface in order to achieve said irregularity. 
Alternativno, na površinu se može nanijeti permanentno magnetski materijal kako bi se dobile navedene nepravilnosti.
In other embodiments, the carbonyl and Z group attached to ring A are disposed meta to each other. In another embodiment, the carbonyl and the Z group attached to ring A are disposed ortho to each other. In one embodiment, the invention provides a compound formula II: 
Spoj prema patentnom zahtjevu 1, naznačen time što su karbonil i Z grupa vezani za prsten A postavljeni u para međusoban položaj ili time što su karbonil i Z grupa vezani za prsten A postavljeni u meta međusobni položaj ili time što su karbonil i Z grupa vezani za prsten A postavljeni u orto međusobni položaj. Spoj prema patentnom zahtjevu 1, formule II:
is selected from methyl, ethyl, propyl or butyl (substituted by one or two groups selected from hydroxyl, phenyl and pyridinyl), cyclopentyl, hydroxycyclopentyl, and oxidotetrahydrothiophenyl, dioxidotetrahydrothiophenyl, tetrahydrofuranyl or oxotetrahydrofuranyl; 
R* je odabran od metila, etila, propila ili butila (supstituiran s jednom ili dvije skupine koje su odabrane od hidroksila, fenila i piridinila), ciklopentila, hidroksiciklopentila, 1 oksidotetrahidrotiofenila, dioksidotetrahidrotiofenila, tetrahidrofuranila ili oksotetrahidrofuranila; ili njegova farmaceutski prihvatljiva sol.
In a preferred embodiment, the antibody, fragment, variant, fusion or derivative comprises a variable light chain (VL) in which CDR1 comprises or consists of the amino acid sequence: 
Protutijelo ili njegov fragment za vezanje antigena koji ima viševalentnu specifičnost vezanja za CD40, pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDRI sadrži ili se sastoji od sekvence amino kiselina:
Feed supplement according to claim 1, wherein said homotrimer, heterotrimer, homotetramer and/or heterotetramer of the said carbohydrate components are present in liquid or solid phase, whereby said MCFA are present in liquid or solid phase, and wherein the feed supplement is present in liquid or solid phase. 
Dodatak prehrani prema bilo kojem od zahtjeva 1 do 4, gdje se spomenuti homo-trimer, hetero-trimer, homo- tetramer i/ili hetero-tetramer spomenute ugljikohidratne komponente nalaze u tekućoj ili krutoj fazi, gdje se spomenuti MCFA-i nalaze u tekućoj ili krutoj fazi, i gdje se dodatak prehrani nalazi u tekućoj ili krutoj fazi.
A pharmaceutical composition for use in the treatment of glaucoma, optic neuritis, or lattice dystrophy comprising a therapeutically effective amount of a monoclonal antibody or a functional part thereof, which recognizes and binds to B-amyloid protein, comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 9; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 10; a light chain CDR3 having the amino acid sequence of SEQ ID NO: 11; a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 12; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 13; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 14. 
HR P20140175 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak namijenjen upotrebi u liječenju glaukoma, optičkog neuritisa ili retikularne distrofije, naznačen time što sadrži terapijski djelotvornu količinu monoklonskog protutijela, ili njegovog funkcionalnog dijela, koje prepoznaje i veže se na B-amiloidni protein, te sadrži CDR1 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12;
The capsule of one of the preceding claims, characterized in that the diameter of inlet sealing membrane (11) is 5 to 15 %, preferably about 10%, larger than the outer diameter of the second flange (9), such that it partially covers partially covers the centring ramp (12) when attached to the second flange (9). 
Kapsula prema jednom od prethodnih zahtjeva, naznačena time, što je promjer zatvarajuće membrane (11) s dovodne strane od 5 do 15%, a posebice oko 10% veći od vanjskog promjera druge prirubnice (9).
Anhydrous AICI3 (219 g., 1.64 moles) was added in portions over a 35 to 40 min. period to a stirred solution of 3,4-dichlorobenzoyl chloride (313.5 g., 1.50 moles) in benzene (1.1251.) and dichloromethane (75 ml.), with the mixture maintained at 3 to 5°C. during the addition period. 
A) 3.4-Diklorobenzofenon Anhidrirani AlCl; (219 g., 1.64 mola) dodaje se u obrocima tijekom perioda od 35 do 40 min. miješanoj otopini 3,4-diklorobenzoilklorida (313.5 g., 1.50 mola) u benzolu (1.125 ml.)
extend over the total axial length of the spring. 
preko cijele aksijalne dužine (L) opruge (1).
In other embodiments, the condition is an eye disorder, such as uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis or a form of conjunctivitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 45, naznačen time da je poremećaj oka uveitis, makularna degeneracija, glaukom, dijabetički makularni edem, blefaritis, dijabetička retinopatija, bolest ili poremećaj endotela rožnice, upala nakon operacije, suho oko, alergijski konjunktivitis, ili oblik konjunktivitisa.
The method of embodiment 21, wherin the mRNA encodes a functional erythropoietin, a-galactosidase, LDL receptor, Factor VIII, Factor IX, a-L-iduronidase, iduronate sulfatase, heparin-N-sulfatase, a-N-acetylglucosaminidase, galactose 6-sultatase, B-galactosidase, lysosomal acid lipase or arylsulfatase-A polypeptide; and (b) a transfer vehicle, wherein following administration of said composition said mRNA is expressed in a target cell to produce a functional secreted polypeptide. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje polipeptid kodiran s mRNA predstavlja polipeptid eritropoetina, a-galaktozidazni polipeptid, polipeptid LDL receptora, faktora VIII, faktora IX, a-L-iduronidaze, iduronat sulfataze, heparin-N-sulfataze, a-N-acetilglukozaminidaze, galaktoza 6-sulfataze, f3- galaktozidaze, lizozomske kisele lipaze ili arilsulfataze-A.
In one embodiment, the pharmaceutical composition is in the form of a powder, granules, tablets, or a lyophilate/lyophilisate. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 10, naznačen time, da je u obliku praška, granula, tableta ili liofilata/liofilizata.
As shown in Figures 3 and 3A, the heat conducting means includes a conductive rod 99 and the foil lined tube 14. 
Kao što je prikazano na Slikama 3 i 3A, sklop za provođenje topline uključuje provodljivi štap 99 i cjev 14 koja je obložena folijom.
The device (1) according to any one of the preceding claims, wherein said side skirt (23) of said cavity (20) has an external surface of a metallic material and/or of a ceramic material. 
Uređaj (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da navedena bočna oplata (23) navedene šupljine (20) ima vanjsku površinu od metalnog materijala 1 / ili od keramičkog materijala.
The compound according to claim 11, wherein the compound is 2-allyl- 4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-alil-4,5-dihidroksiizoftalonitril.
Combustion modifying additives also may be added to these fibrous fuels. 
Na ova vlaknasta goriva također se mogu dodati aditivi za modificiranje izgaranja.
The method of claim 1, wherein the CTLA4-Ig molecules of the composition are characterized by less than or equal to 2.5 area percent CTLA4-Ig high molecular weight species as determined by size exclusion chromatography and spectrophotometric detection. 
Pripravak koji sadrži CTLA4-Ig molekule i naznačen je time što je: (a) prosječni molarni omjer N-acetil neuraminske kiseline (NANA) prema CTLA4-Ig molekulama od 8.0 do 11.9, i (b) manji ili jednak 2.0 posto površine CTLA4-Ig visoke molekulske težine kako je određeno kromatografijom isključenja po veličini i spektrofotometrijskim otkrivanjem.
Apoaequorin for use according to claim 1, wherein the apoaequorin is administered by injection. 
2. < Apoekvorin za uporabu prema zahtjevu 1, naznačen time, da se apoekvorin primjenjuje putem injekcije.
wherein the at least one source of a water soluble lithium compound is a polymeric salt of lithium, said polymeric salt of lithium being preferably a homopolymer and/or copolymer of acrylic acid, wherein at least 40 mole-% of the acid sites of said polymeric salts of lithium are neutralized by lithium. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 18 do 22, pri čemu je najmanje 40 mol-%, poželjno 45 do 80 mol-% i poželjnije 95 do 100 mol-% kiselinskih mjesta navedenih polimernih soli litija neutralizirano litijem.
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Rc i Ry su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila, Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran iz skupine koja se sastoji od
The patient is one who has exhibited abnormal biomarkers of liver function ith Example 1. During the course of pirfenidone treatment, patients exhibidisclosure for administering pirfenidone to a patient for treating idiopathic pulmonary fibrosis. In particular, the disclosure includes pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 -puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 2400 mg/dan ili 2403 mg/dan.
Add 3.6 mL (0.9 mmol) of the aqueous solution dropwise. 
Ukapa se 3,6 ml (0,9 mmol) vodene otopine.
the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof, wherein: 
(o) njegove farmaceutski prihvatljive kisele ili bazne adicijske soli, njegovi kvaterni amini, njegovi stereokemijski izomerni oblici, njegovi tautomerni oblici i njegovi N-oksidni oblici, naznačen time da:
It is also possible to mix different species (and materials). 
Također je moguće miješati različite vrste (i materijale).
12, wherein the degree of substitution of the hydroxyethyl group is selected such that a weight percent solids at a viscosity of 1000 cps and a temperature of 150 degrees Fahrenheit is in a range from 17 percent to 21 percent. 
Zidna gips ploča prema zahtjevu 4, naznačena time, da je maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6*C (150"F) u rasponu od 17 do 21%.
can be hydrogen, together with R5 or R7 can be a double bond; or together with R7 can be an a or B -CH2 group; 
može biti vodik, zajedno s R5 ili R7 može biti dvostruka veza; ili zajedno s R7 može biti a ili B -CH2 skupina;
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™ 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja kada je ispitivan u komparativnoj kliničkoj studiji je bioekvivalentan sa komercijalnim proizvodom OxyContinTM,
The kit of claim 4 wherein recombinase accessory proteins are included, such as single-stranded binding protein gp32 and/or recombinase loading agent UvsY. 
Komplet iz patentnog zahtjeva 4 pri čemu su proteini koji prate rekombinazu obuhvaćeni, kao što je gp32 jednolančani vezni protein 1/ili UvsY agens učitavanja rekombinaze.
a binding domain capable of binding to the extracellular domain of the mutated human PSMA having an amino acid sequence as depicted in SEQ ID NO: 447, wherein the amino acid residues at positions 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 and 721 are mutated to the corresponding amino acid residues of the wt rodent PSMA, but not to the extracellular domain of the rodent PSMA; 
(a) vežuća domena, koja se može vezati na izvanstaničnu domenu mutiranog ljudskog PSMA s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 447, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 7171721 mutirani u odgovarajuće aminokiselinske ostatke PSMA divljeg tipa glodavca, no ne i na izvanstaničnu domenu PSMA glodavca;
The method of claim 4 wherein the drive signal having the first frequency or the drive signal having the second frequency have a variable pulse duration and/or timing. 
Sustav u skladu sa zahtjevom 4, naznačen time, da su upravljačka sredstva nadalje podešena da provode upravljački signal koji ima prvu frekvenciju ili drugu frekvenciju s promjenjivim trajanjem pulsa i/ili izborom vremena.
the electrodes are configured to align and connect to the electrodes of a vehicle cigarette lighter socket; the material infused with the fragrance is a solid in the shape of a flat ring; and 
HR P20171283 T1 se kod materijala (114) koji je natopljen aromom, radi o krutoj tvari u obliku plosnatog prstena; i kapica (116) obuhvaća ventil (110) koji je djelotvoran za raspršivanje arome.
Conductometer (Metrohm or equivalent). Materials 
- < Konduktometar (Metrohm ili njegov ekvivalent).
A process for preparing a kit for preparing an immunogenic composition, comprising preparing an oil-in-water emulsion by the process of any one of claims 3 to 19, packaging the emulsion in a first container, and combining the first container in kit form with a second container, wherein the second container contains an immunogen. 
Postupak za dobivanje kita za dobivanje imunogenog pripravka, naznačen time da sadrži pripremu emulzije ulja u vodi postupkom prema bilo kojem od zahtjeva 1 do 13, pakiranje emulzije u prvi spremnik, te miješanja prvog spremnika u obliku kita sa drugim spremnikom, pri čemu drugi spremnik sadrži imunogen.
determining whether there is a decrease in the levels of the soluble molecule between the first and second biological samples, wherein the decrease correlates with a decrease in alpha-4 integrin activity in the individual, and thereby determining whether there is a difference in alpha-4 integrin activity in the individual after administration of the alpha-4 integrin inhibitor compared with before administration of the alpha-4 integrin inhibitor; and 
određivanje da li postoji smanjenje u razinama topive molekule između prvog i drugog biološkog uzorka, pri čemu smanjenje korelira sa smanjenjem u alfa-4 integrinskoj aktivnosti kod pojedinca, i time određuje postoji li razlika u alfa -4 integrinskoj aktivnosti kod pojedinca nakon primjene alfa-4 integrinskog inhibitora u usporedbi sa prije primjene alfa-4 integrinskog inhibitora; i
A pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound and at least one GLP-1 R (glucagon-like peptide-1 receptor) agonist for use in treating diabetes, wherein the pharmaceutical composition further comprises an acceptable pharmaceutical carrier, diluent or excipient selected from the group consisting of sterile water, saline containing about 0.9% mg/ml benzyl alcohol, Hank's solution, Ringer's-lactate, lactose, dextrose, sucrose, trehalose, sorbitol, and mannitol. 
Farmaceutski pripravak koji sadržava barem jedan spoj FGF-21 (fibroblastni čimbenik rasta 21) 1 barem jedan agonist GLP-1R (receptora glukagonu sličnog peptida-1) agonist za uporabu za liječenje dijabetesa, naznačen time što farmaceutski pripravak nadalje sadrži prihvatljiv farmaceutski nosač, razrjeđivač ili pomoćnu tvar odabranu iz skupine koja se sastoji od sterilne vode, otopine soli koja sadrži oko 0.9% mg/ml benzil alkohola, Hankovu otopinu, Ringerov laktat, laktozu, dekstrozu, saharozu, trehalozu, sorbitol, i manitol.
The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
The major clinical unmet need in schizophrenia is the treatment of negative and cognitive symptoms, since even the latest generation of atypical antipsychotic drugs offers little improvement. 
Glavna klinička potreba kod šizofrenije je liječenje negativnih i kognitivnih simptoma jer čak i zadnje generacije atipičnih antipsihotičnih lijekova nude slabo poboljšanje.
The process as claimed in claim 1, wherein the temperature used in Step (vii) is 62 °C to 63 °C. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je temperatura korištena u Koraku (vii) 62 *C do 63 "€.
Y represents a hydrogen atom or any structure of the following formulas [3']: 
Z' predstavlja bilo koja struktura prema slijedećoj skupini formula [4']:
2000), in its monograph “Omega-3 acid ethyl esters”, a mixture of ethyl esters of omega-3 polyunsaturated acids, typically represented by EPA and DHA, prescribes the direct control of the oxidation and polymerization by-products (defined “oligomers”, as a whole, which are not detectable by gaschromatographic route), by means of a specific exclusion chromatography in liquid phase (gel permeation GPC, well known in the art). 
2000), u svojoj monografiji "Omega-3 kiselinski etil esteri", smjesa etil estera omega-3 polinezasićenih kiselina, tipično predstavljenih s EPA 1 DHA, propisuje direktnu kontrolu oksidacijskih i polimerizacijskih nusprodukata (definiranih kao "oligomeri", u cjelini, koji se ne mogu detektirati pomoću plinske kromatografije), pomoću specifične ekskluzijske kromatografije u tekućoj fazi (gel permeacijska GPC, dobro poznata u struci).
The compound for use according to item 26, wherein the cancer is leukemia. 
Spoj za uporabu u sklađu s patentnim zahtjevom 19, naznačen time što je rak leukemija.
a saccharification step wherein the liquefied lignocellulosic material is hydrolysed in the at least first container and/or in at least a second container. 
korak saharifikacije pri čemu ukapljeni lignocelulozni materijal hidrolizira barem u prvom spremniku i/ili barem u drugom spremniku.
Water Content of Alkaloid (nicotine) containing Lozenges Manufactured with Citrate Buffer stored at 25° C./60% RH. 
Sadržaj vode tableta koje sadrže alkaloid (nikotin) proizvedenih sa citratnim puferom čuvane na 252C/60% relativne vlažnosti Grupa
Process according to any of claims 1 to 12, characterized in that step b) is carried out at a temperature of between 60°C and 100°C, advantageously 80°C. 
Postupak prema bilo kojem zahtjevu od 1 do 14, naznačen time da se sredstvo za blokiranje slobodnog lantanida, poželjno polikarboksilna kiselina, dodaje u koraku b).
a performance booster selected from an alkoxylated polyethyleneimine or an alkyl-(hydroxyethyl) dimethyl ammonium chloride and mixtures thereof in a quantity higher than 0.1% by weight with respect to the total weight of the additive composition with integrated action, more preferably a mixture of alkoxylated polyethylene amine and alkyl-(hydroxyethyl) dimethyl ammonium chloride in a quantity ranging from 0.1% to 5% by weight, even more preferably in a quantity equal to 2.5% by weight. 
najmanje jednog pojačivača performansi odabranog između alkoksiliranog polietilenimina ili alkil-(hidroksietil) dimetil amonij klorida i njihovih smjesa u količini većoj od 0.1% masenih u odnosu na ukupnu masu kompozicije aditiva sa integriranim djelovanjem; anionskog surfaktanta koji je natrij lauret sulfat (LES) u količini većoj od 0.1% masenih u odnosu na ukupnu masu kompozicije aditiva sa integriranim djelovanjem;
A method of claim 1, for synthesizing amine E5 comprising an acetylation-reduction of oxime E4 by reacting said oxime E4 with acetic anhydride and hydrogen in the presence of a hydrogenation catalyst. 
# Å u Eđ reakcijom navedenog oksima E4 s anhidridom octene kiseline i vodikom uz prisutnost katalizatora hidrogenizacije.
The reaction mixture was allowed to cool to room temperature and was poured into a separating funnel. 
Reakcijska smjesa se ostavi ohladiti na sobnu temerturu i ulije se u lijevak za odijeljivanje.
On the organic component - lignite (peat, sawdust) of a fraction within 0 and 3 mm - there were dosed the solid chemicals (urea, K-salt, Thomas slag etc.) under stirring at 250 to 300 rev./min. during 1 to 2 minutes. 
Na organsku komponentu - mladi ugljen (treset, piljevina), frakcije od 0 do 3 mm, doziraju se čvrste kemikalije (urea, K-sol, Thomasova troska itd.), pri okretanju mješalice s 250 do 300 okretaja u minuti u trajanju od 1 do 2 minute.
The pharmaceutical combination for use according to claim 1, wherein the patient to be treated is obese. 
Farmaceutska kombinacija za uporabu prema zahtjevu 1, naznačena time da pacijent koji se treba liječiti je pretio.
The method of claim 12, wherein said biological sample is a DNA sample extracted from a corn plant. 
(1) je spomenuti DNA izdvojen iz biološkog uzorka biljke kukuruza; i / ili
wherein the foldable panels of each said unit structure are foldable into a space efficient configuration disposed closely adjacent the roof panel to facilitate shipping and packaging. The modular data center of claim 8, further comprising a plurality bridging ceiling panels disposed between adjacent ones of the unit structures, to assist in forming the hot aisles. 
Modularni podatkovni centar prema zahtjevu 2, naznačen time što su sklopive ploče (32) svake navedene konstrukcijske jedinice sklopive u prostorno učinkovitoj konfiguraciji smještene u neposrednoj blizini krovne ploče (42) kako bi se olakšalo otpremanje i pakiranje.
S-ketamine HCl; wherein the S-Ketamine HCl is present in an amount of about 161.4 mg/ml; 
S-ketamin HCl; pri čemu se S-Ketamin HCl nalazi u količini od oko 161.4 mg/ml;